Source comparison
PT-141 vs Cialis Mechanism: Full Comparison
Below is a side-by-side comparison of PT-141 (bremelanotide) and Cialis (tadalafil) across mechanism, pharmacokinetics, and clinical use. Each parameter reflects documented pharmacological and clinical trial data. Primary Mechanism MC4R agonist in hypothalamus
This comparison does not assign a generated winner or score.
- Below is a side-by-side comparison of PT-141 (bremelanotide) and Cialis (tadalafil) across mechanism, pharmacokinetics, and clinical use. Each parameter reflects documented pharmacological and clinical trial data.
- Primary Mechanism
- MC4R agonist in hypothalamus. Central libido modulation
- PDE5 inhibitor in corpus cavernosum. Peripheral vasodilation
- PT-141 treats desire deficits; Cialis treats vascular/mechanical dysfunction
- Site of Action
- Central nervous system (paraventricular nucleus)
- Peripheral smooth muscle (genital vasculature)
- No mechanistic overlap. Can theoretically be combined
- Onset of Effect
- 45 minutes to 2 hours post-injection
- 30 minutes to 2 hours post-oral dose
- PT-141 requires advance planning; tadalafil allows spontaneity (especially daily dosing)
- Duration of Effect
- 8–12 hours (subjective arousal)
- Up to 36 hours (vascular effect)
- Tadalafil's extended window favors on-demand use
- Half-Life
- 2.7 hours
- 17.5 hours
- Tadalafil supports daily dosing; PT-141 is event-driven only
- Route of Administration
- Subcutaneous injection
- Oral tablet
- PT-141 requires injection proficiency; tadalafil is non-invasive
- FDA-Approved Indication
- HSDD in premenopausal women
- ED in men; BPH at 5 mg daily
- Approved populations do not overlap. Off-label use common
- Common Side Effects
- Nausea (40%), flushing, hypertension
- Headache (15%), nasal congestion, dyspepsia
- Side effect profiles diverge due to distinct mechanisms
- Contraindications
- Uncontrolled hypertension, cardiovascular disease
- Concurrent nitrate therapy (severe hypotension risk)
- Neither compound is universally safe. Prescriber assessment required
- Efficacy in Desire Disorders
- Demonstrated in RECONNECT trials (HSDD)
- No evidence for central desire enhancement
- PT-141 is the only FDA-approved pharmacotherapy for low libido
- Efficacy in Vascular ED
- No evidence for direct vascular benefit
- Robust IIEF-EF improvement across ED etiologies
- Tadalafil remains first-line for vasculogenic dysfunction
- Professional Assessment
- Use when low desire is the primary barrier and vascular function is intact
- Use when erectile rigidity or sustained blood flow is the limiting factor. Desire must be present for effect